Drug Trial Radar · NCT06717698
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
465
Planned (sponsor's estimate)
Start
Dec 2, 2024
Primary completion
Sep 1, 2026
Study completion Sep 17, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.
Conditions
- Chronic Kidney Disease
Interventions
NNC0519-0130Drug
NNC0519-0130 will be administered subcutaneously.
PlaceboDrug
Placebo matching NNC0519-0130 will be administered subcutaneously.
SemaglutideDrug
Semaglutide will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in urinary albumin-to-creatinine ratio (UACR) at week 12Time frame: From baseline (week 0) to end of a given maintenance dose period (week 12)
- Change in urinary albumin-to-creatinine ratio (UACR) at week 24Time frame: From baseline (week 0) to end of a given maintenance dose period (week 24)
- Change in urinary albumin-to-creatinine ratio (UACR) at week 36Time frame: From baseline (week 0) to end of a given maintenance dose period (week 36)
Locations
147 sites in 14 countries. Site status is shown where the registry gives one.
N America Res Inst - San Dimas
San Dimas, California · Active not recruiting
NorCal Endocrinology and Internal Medicine
San Ramon, California · Active not recruiting
Rocky Mount Reg VA Med-DN
Aurora, Colorado · Completed
Northeast Research Institute
Fleming Island, Florida · Active not recruiting
Encore Medical Research LLC
Hollywood, Florida · Active not recruiting
Northeast Research Institute
Saint Augustine, Florida · Active not recruiting
Clinical Research of Cent FL
Winter Haven, Florida · Completed
Endeavor Health
Skokie, Illinois · Completed
Velocity Clin. Res Valparaiso
Valparaiso, Indiana · Active not recruiting
Elite Research Center
Flint, Michigan · Completed
Clinical Research Consultants
Kansas City, Missouri · Active not recruiting
Albany Medical College
Albany, New York · Active not recruiting
Carteret Medical Group
Morehead City, North Carolina · Active not recruiting
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina · Active not recruiting
Davita Clinical Research
El Paso, Texas · Active not recruiting
Clinical Advancement Center
San Antonio, Texas · Active not recruiting
Tekton Research
San Antonio, Texas · Completed
Providence Medical Research Center
Spokane, Washington · Active not recruiting
Centro de Investigaciones Metabólicas
City of Buenos Aires, Argentina · Active not recruiting
Instituto de Cardiología de Corrientes
Corrientes, Argentina · Active not recruiting
Instituto de Investigaciones Clinicas Mar Del Plata
Mar del Plata, Argentina · Active not recruiting
Centro Médico CIMEL
Lanús Este, Buenos Aires, Argentina · Active not recruiting
Renalida
Mar del Plata, Buenos Aires, Argentina · Active not recruiting
Castle Hill Medical Centre
Castle Hill, New South Wales, Australia · Active not recruiting
Gosford Renal Research
Gosford, New South Wales, Australia · Active not recruiting
Heart of Australia
Chelmer, Queensland, Australia · Active not recruiting
Melbourne Renal Research Group
Reservoir, Victoria, Australia · Not yet recruiting
Sunshine Hospital - Western Centre for Health Research and Education
St Albans, Victoria, Australia · Active not recruiting
Hospital do Rim e Hipertensao Fundacao Oswaldo Ramos
São Paulo, Brazil · Active not recruiting
Quanta Diagnóstico Nuclear / Medicina Nuclear Alto da XV
Curitiba, Paraná, Brazil · Active not recruiting
Instituto Pró-Renal Brasil
Curitiba, Paraná, Brazil · Active not recruiting
Centro de Diabetes Curitiba
Curitiba, Paraná, Brazil · Active not recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
SRH - Zdrave EAD
Bankya, Bulgaria · Active not recruiting
Medical centre Zdrave 1 OOD
Kozloduy, Bulgaria · Active not recruiting
Nader Yabrudi - ASMPVBE Individual practice
Smolyan, Bulgaria · Active not recruiting
Medical Centre Acad. Iv. Penchev EOOD
Sofia, Bulgaria · Completed
Medical Centre Acad. Iv. Penchev EOOD
Sofia, Bulgaria · Active not recruiting
USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
Sofia, Bulgaria · Active not recruiting
Showing 40 of 147 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.